Laboratory methods in the haemostatic laboratory

Christine Mannhalter; Peter Quehenberger

doi:10.1160/TH06-10-0589

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2006; 96(05): 545-546
DOI: 10.1160/TH06-10-0589

Theme Issue Editorial Focus

Schattauer GmbH

Laboratory methods in the haemostatic laboratory

Authors

Christine Mannhalter

¹Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University Vienna, Vienna, Austria
Peter Quehenberger

¹Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University Vienna, Vienna, Austria

Abstract

Full Text

References

References
1 Sorensen B, Ingerslev J. Tailoring haemostatic treatment to patient requirements – an update on monitoring haemostatic response using thrombelastography. Haemophilia 2005; (Suppl. 01) 1-6.
2 Hemker HC, Al Dieri R, De Smet E. et al. Thrombin generation, a function test of the haemostatic-thrombotic system. Thromb Haemost 2006; 96: 553-61.
3 Dargaud Y, Trzeciak MC, Bordet JC. et al. Use of calibrated automated thrombinography± thrombomodulin to recognise the prothrombotic phenotype. Thromb Haemost 2006; 96: 562-7.
4 Brummel-Ziedins KE, Vossen CY, Butenas S. et al. Thrombin generation profiles in deep venous thrombosis. J Thromb Haemost 2005; 03: 2497-505.
5 Hron G, Kollars M, Binder BR. et al. Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. J Am Med Assoc 2006; 296: 397-402.
6 Agnelli G, Iorio A, Renga C. et al. Prolonged antithrombin activity of low-molecular-weight heparins. Clinical implications for the treatment of thromboembolic diseases. Circulation 1995; 92: 2819-24.
7 Marcucci R, Gori AM, Giannotti F. et al. Markers of hypercoagulability and inflammation predict mortality in patients with heart failure. J Thromb Haemost 2006; 04: 1017-22.
8 Ofosu FA. Review: Laboratory markers quantifying prothrombin activation and actions of thrombin in venous and arterial thrombosis do not accurately assess disease severity or the effectiveness of treatment. Thromb Haemost 2006; 96: 568-77.
9 Eickelboom JW, Hirsh J. Monitoring unfractionated heparin with the aPTT: Time for a fresh look. Thromb Haemost 2006; 96: 547-52.
10 Dati F, Hafner G, Erbes H. et al. ProC Global: the first functional screening assay for the complete protein C pathway. Clin Chem 1997; 43: 1719-23.
11 Tripodi A, Akhavan S, Asti D. et al. Laboratory screening of thrombophilia. Evaluation of the diagnostic efficacy of a global test to detect congenital deficiencies of the proteinC anticoagulant pathway. Blood Coagul Fibrinolysis 1998; 09: 485-9.
12 Grand'Maison A, Bates SM, Johnston M. et al. “ProC Global”: a functional screening test that predicts recurrent venous thromboembolism. Thromb Haemost 2005; 93: 600-4.
13 Endrikat J, Noah M, Gerlinger C. et al. Impact of oral contraceptive use on APC-resistance: a prospective, randomized clinical trial with three low-dose preparations. Contraception 2001; 64: 217-22.
14 Wu O, Robertson L, Twaddle S. et al. Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study. Health Technol Assess 2006; 10: 1-110.
15 Galit S, Aberbach I, Schliamser L. et al. Evaluation of ProC Global assay in women with a history of VTE on hormonal therapy. Thromb Haemost 2006; 96: 578-83.